Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients

CONCLUSION: Overall, the present study indicates that persistence rates are low in all age groups for both TAM and AI treatment. We found several factors (e.g., physician specialty, younger age, and type of endocrine therapy) to be associated with an increased risk for non-persistence.PMID:36149512 | DOI:10.1007/s00432-022-04376-5

Source: Clinical Breast Cancer - September 23, 2022 Category: Cancer & Oncology Authors: Niklas Gremke Sebastian Griewing Saket Chaudhari Swati Upadhyaya Ivan Nikolov Karel Kostev Matthias Kalder Source Type: research